PhoreMost has announced the appointment of Dr Lorenz Mayr to its board as non-executive director.

Dr Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER target discovery platform and guide the development of the company’s drug discovery programme.

He is currently chief technology officer at GE Healthcare Life Sciences, where he is responsible for R&D strategy and innovation across all life sciences business areas. He has extensive global experience in pharmaceutical R&D, including holding positions as vice president & global head at AstraZeneca and executive director at Novartis Pharmaceuticals and Bayer Pharmaceuticals.

Dr Chris Torrance chief executive officer, PhoreMost, said of the appointment: “Lorenz’s expertise and global industry leadership will be invaluable in shaping PhoreMost’s future development as a fully integrated target identification and drug discovery company. As a key thought leader in functional screening and novel modalities we are particularly proud to welcome him to our Board.”